Home Cart Sign in  
Chemical Structure| 189060-13-7 Chemical Structure| 189060-13-7

Structure of Lapaquistat acetate
CAS No.: 189060-13-7

Chemical Structure| 189060-13-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lapaquistat acetate is a squalene synthase inhibitor with cholesterol-lowering effect.

Synonyms: TAK-475

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lapaquistat acetate

CAS No. :189060-13-7
Formula : C33H41ClN2O9
M.W : 645.14
SMILES Code : O=C(O)CC1CCN(C(C[C@H]2O[C@H](C3=CC=CC(OC)=C3OC)C4=CC(Cl)=CC=C4N(CC(C)(C)COC(C)=O)C2=O)=O)CC1
Synonyms :
TAK-475
MDL No. :MFCD06407873
InChI Key :CMLUGNQVANVZHY-POURPWNDSA-N
Pubchem ID :9874248

Safety of Lapaquistat acetate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00143676 Hypercholesterolemia Phase 3 Completed - -
NCT00286481 Hypercholesterolemia Phase 3 Completed - -
NCT00256178 Hypercholesterolemia Phase 3 Completed - -
NCT00249899 Hypercholesterolemia Phase 3 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - -
NCT00143663 Dyslipidemia Phase 3 Completed - -
NCT00865228 Hypercholesterolemia Phase 2 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - United States, California ... More >> Long Beach, California, United States Sacramento, California, United States San Diego, California, United States United States, Florida Hollywood, Florida, United States Jacksonville, Florida, United States New Port Richey, Florida, United States United States, Illinois Chicago, Illinois, United States United States, Kansas Wichita, Kansas, United States United States, Kentucky Louisville, Kentucky, United States United States, New Jersey Margate, New Jersey, United States United States, North Carolina Charlotte, North Carolina, United States Raleigh, North Carolina, United States Statesville, North Carolina, United States Wilmington, North Carolina, United States Winston-Salem, North Carolina, United States United States, Oregon Medford, Oregon, United States United States, Pennsylvania Perkasie, Pennsylvania, United States Sellerville, Pennsylvania, United States United States, Tennessee Bristol, Tennessee, United States United States, Virginia Norfolk, Virginia, United States Richmond, Virginia, United States United States, Wisconsin Madison, Wisconsin, United States Less <<
NCT00864643 Hypercholesterolemia Phase 2 Completed - -
NCT00890448 - Completed - -
NCT00268697 Hypercholesterolemia Phase 3 Completed - Estonia ... More >> Tallinn, Estonia Tartu, Estonia Latvia Riga, Latvia Russian Federation Moscow, Russian Federation Saratov, Russian Federation Smolensk, Russian Federation St. Petersburg, Russian Federation Tyumen, Russian Federation Serbia Kragujevac, Serbia Less <<
NCT00249912 Hypercholesterolemia Phase 3 Completed - -
NCT00251680 Type 2 Diabetes Phase 3 Completed - -
NCT00532311 Hypercholesterolemia Phase 3 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - -
NCT00813527 Hyperlipidemias Phase 2 Completed - -
NCT00487994 Dyslipidemia Phase 3 Completed - -
NCT00868127 Hypercholesterolemia Phase 3 Completed - -
NCT00263081 Hypercholesterolemia Phase 3 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - United States, Ohio ... More >> Cincinnati, Ohio, United States Columbus, Ohio, United States Canada Québec, Canada France Paris, France Strasbourg, France Israel Jerusalem, Israel Poland Bialystok, Poland Warszawa, Poland Zabrze, Poland United Kingdom Manchester, United Kingdom Less <<
NCT00532558 Hypercholesterolemia Phase 3 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.55mL

0.31mL

0.16mL

7.75mL

1.55mL

0.78mL

15.50mL

3.10mL

1.55mL

References

 

Historical Records

Categories